1373555-86-2

Upstream product

• 1373555-13-5 C₃₁H₃₁FO₉S 
• 1103738-19-7 ((3aS,5R,6S,6aS)-6-hydroxy-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxol-5-yl)(morpholin-4-yl)methanone 
• 1373555-14-6 C₃₀H₃₁FO₇S₂ 
• 1373555-12-4 C₂₆H₂₅FO₅S 
• 898566-17-1 (2-(4-fluorophenyl)-5-[(5-iodo-2-methylphenyl)methyl]thiophene) 

Downstream Products

• 1373555-05-5 (2S,3R,4R,5S,6R)-2-[3-((5-(4-fluorophenyl)thienyl)-2-methylene)-4-chloro-phenyl]-6-methylsulfonyltetrahydropyran-3,4,5-triol 

Relevant academic research and scientific papers

C-ARYL GLUCOSIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF

The present invention relates to a C-aryl glucoside derivative of Formula (I) below, a preparation method therefor and a use thereof, wherein X, R1, R2, R3, R4, m and n are as defined in specification. The deriv

C-ARYLGLUCOSIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF

The present invention relates to a C-aryl glucoside derivative of Formula (I) below, a preparation method therefor and a use thereof, wherein X, R1, R2, R3, R4, m and n are as defined in specification. The derivative of the present invention is a sodium-glucose co-transporter 2 (SGLT-2) inhibitor associated with glucose reabsorption of bowel or kidney, and has a good urine glucose excreting effect, thus being useful as a therapeutic agent for treating diabetes and related diseases.